查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2028313

神經性疼痛市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類，並提供 2026-2034 年的洞察和預測

Neuropathic Pain Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 155 Pages | 商品交期: 2-3個工作天內

價格

神經性疼痛市場的成長要素

受慢性疾病盛行率上升和對有效疼痛管理療法需求不斷成長的推動，全球神經性疼痛市場正經歷穩定成長。該市場在2025年的價值為82.6億美元，預計到2026年將成長至88.3億美元，並在2034年達到167.8億美元。北美在2025年佔市場主導地位，市佔率達50.66%，主要得益於製藥公司強大的市場影響力和較高的品牌知名度。

神經性疼痛是由神經系統損傷或功能障礙引起的，通常會發展為慢性疼痛，並嚴重影響患者的生活品質。常見的治療方法包括藥物治療，例如抗驚厥藥和抗憂鬱症，以及醫療設備和手術介入。糖尿病、癌症和帶狀皰疹等疾病的日益流行是促使需要接受治療的患者群體不斷擴大的主要因素。

市場趨勢

神經病變疼痛市場的關鍵趨勢是越來越重視新藥的研發。製藥公司正積極進行臨床試驗，以推出療效較佳、副作用較少的先進藥物。例如，目前正在進行的針對神經病變和三叉神經痛的創新候選藥物的臨床試驗有望拓寬治療選擇。

另一個值得關注的趨勢是朝向標靶治療和個人化醫療的轉變。各公司正利用先進技術和精準醫療治療方法。預計這一趨勢將在預測期內改善治療效果並推動市場成長。

市場促進因素

糖尿病、癌症和神經系統疾病等慢性疾病負擔日益加重，是推動市場成長的主要因素。在全球範圍內，相當一部分人口患有糖尿病，而糖尿病是神經病變疼痛的主要原因之一。此外，全球癌症患者數量的不斷增加也導致化療引起的神經病變日益增加。

人口老化也是推動市場擴張的重要因素。由於老年人更容易患上帶狀皰疹後遺症神經痛和糖尿病神經病變等疾病，因此對有效的疼痛管理解決方案的需求日益成長。

此外，人們對神經病變疼痛的認知不斷提高，以及先進治療方法的普及，促使更多患者尋求治療。政府措施和醫療基礎設施的改善也推動了市場成長。

市場限制因素

儘管前景樂觀，但市場仍面臨一些挑戰。神經病變疼痛藥物的副作用，例如頭暈、噁心和疲勞，常常阻礙患者繼續治療。這些副作用迫使患者考慮其他治療方法，包括醫療設備和外科手術。

此外，高昂的治療費用和發展中地區有限的醫療資源可能會阻礙市場成長。部分地區較低的認知水平和醫療基礎設施不足也限制了先進治療方法的普及。

細分分析

依藥物類別分類，抗癲癇藥物在2026年佔市場主導地位，市佔率達28.92%。這主要得益於Gabapentin和Pregabalin等藥物在糖尿病神經病變治療的廣泛應用。其他藥物類別，包括抗憂鬱症和鴉片類藥物，也做出了顯著貢獻，但新興療法預計將成長更快。

按應用領域分類，化療引起的神經病變預計在2026年將佔最大佔有率，達到39.48%，這主要受接受治療的癌症患者人數不斷增加的影響。鑑於全球糖尿病盛行率的上升，糖尿病性神經病變病變預計也將快速成長。

就給藥途徑而言，由於口服藥物種類繁多，預計到2026年，口服藥物將佔市場主導地位，市場佔有率高達77.15%。此外，隨著注射療法研究的不斷深入，腸外給藥途徑也正在蓬勃發展。

按分銷管道分類，預計到2026年，零售藥局將以68.61%的市佔率佔主導地位，這主要得益於藥品取得的便利性。隨著越來越多的消費者傾向於便捷的購買方式，線上藥局也正在迅速崛起，成為一個快速成長的細分市場。

區域趨勢

預計到2025年，北美地區的經濟總量將達到41.8億美元，到2026年將達到45.1億美元，主要得益於活躍的研發活動和高疾病盛行率。美國仍然是該地區最大的經濟貢獻國。

預計到2025年，歐洲市場規模將達到22.8億美元，到2026年將達到24.2億美元，主要得益於糖尿病和癌症病例的增加。亞太地區2025年的市場規模為10億美元，預計到2026年將成長至10.7億美元，主要受醫藥研發投資增加的推動。

拉丁美洲、中東和非洲是新興市場，人們意識的提高和醫療基礎設施的改善正在推動其成長。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 2025年主要國家及次區域神經性疼痛盛行率
  • 管道分析：按主要公司分類
  • 新產品發布：按主要公司分類
  • 主要產業趨勢（合併、收購、合作等）
  • 新冠疫情對市場的影響

第5章：2021-2034年全球神經性疼痛市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • 抗驚厥藥物
    • 三環抗憂鬱藥物（TCAs）
    • 鴉片類藥物
    • 辣椒素類物質
    • 其他
  • 市場分析、洞察與預測：按應用領域分類
    • 糖尿病神經病變
    • 化療引起的神經病變
    • 坐骨神經神經病變
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美神經性疼痛市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲神經性疼痛市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區神經性疼痛市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 澳洲
    • 中國
    • 印度
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲神經性疼痛市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲神經性疼痛市場分析、洞察與預測（2021-2034年）

  • 國家
    • 南非
    • GCC
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Almatica
    • Azurity Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Viatris Inc.
    • Supernus Pharmaceuticals, Inc.
    • Novartis AG
    • Accord Healthcare
    • Focus Health Group
    • Amneal Pharmaceuticals LLC
    • Abbott
    • Teva Pharmaceutical Industries Ltd.
Product Code: FBI110546

Growth Factors of neuropathic pain Market

The global neuropathic pain market is witnessing steady growth due to the rising prevalence of chronic diseases and increasing demand for effective pain management therapies. The market was valued at USD 8.26 billion in 2025, increased to USD 8.83 billion in 2026, and is projected to reach USD 16.78 billion by 2034. North America dominated the market with a 50.66% share in 2025, supported by strong pharmaceutical presence and high awareness levels.

Neuropathic pain arises from damage or dysfunction in the nervous system and is often chronic, significantly affecting patients' quality of life. Common treatment options include medications such as anticonvulsants and antidepressants, along with medical devices and surgical interventions. Increasing cases of diabetes, cancer, and shingles are major contributors to the growing patient pool requiring treatment.

Market Trends

A key trend in the neuropathic pain market is the increasing focus on research and development for novel therapeutics. Pharmaceutical companies are actively conducting clinical trials to introduce advanced drugs with improved efficacy and fewer side effects. For instance, ongoing trials for innovative drug candidates targeting polyneuropathy and trigeminal neuralgia are expected to expand treatment options.

Another notable trend is the shift toward targeted and personalized therapies. Companies are leveraging advanced technologies and precision medicine approaches to develop treatments tailored to specific patient conditions. This trend is expected to improve treatment outcomes and drive market growth over the forecast period.

Market Drivers

The growing burden of chronic diseases such as diabetes, cancer, and neurological disorders is a major driver of market growth. Globally, a significant proportion of the population suffers from diabetes, which is a leading cause of neuropathic pain. Additionally, chemotherapy-induced neuropathy is increasing due to the rising number of cancer cases worldwide.

The aging population is another important factor contributing to market expansion. Elderly individuals are more susceptible to conditions such as post-herpetic neuralgia and diabetic neuropathy, thereby increasing the demand for effective pain management solutions.

Furthermore, increasing awareness about neuropathic pain and the availability of advanced therapeutics are encouraging more patients to seek treatment. Government initiatives and improved healthcare infrastructure are also supporting market growth.

Market Restraints

Despite the positive outlook, the market faces certain challenges. Side effects associated with neuropathic pain medications, such as dizziness, nausea, and fatigue, often limit patient adherence to treatment. These adverse effects encourage patients to explore alternative treatment options, including medical devices and surgical procedures.

Additionally, high treatment costs and limited accessibility in developing regions may hinder market growth. The lack of awareness and inadequate healthcare infrastructure in some regions also restricts the adoption of advanced therapies.

Segmentation Analysis

By drug class, the anticonvulsants segment dominated the market with a 28.92% share in 2026, driven by the widespread use of drugs such as gabapentin and pregabalin for diabetic neuropathy. Other segments, including antidepressants and opioids, also contribute significantly, while emerging therapies are expected to witness faster growth.

By application, chemotherapy-induced neuropathy held the largest share of 39.48% in 2026, due to the increasing number of cancer patients undergoing treatment. The diabetic neuropathy segment is expected to grow rapidly owing to the rising prevalence of diabetes globally.

By route of administration, the oral segment dominated with a 77.15% share in 2026, supported by the availability of a wide range of oral medications. Parenteral administration is also gaining traction due to ongoing research in injectable therapies.

By distribution channel, retail pharmacies led the market with a 68.61% share in 2026, attributed to easy accessibility of medications. Online pharmacies are emerging as a fast-growing segment due to increasing consumer preference for convenient purchasing options.

Regional Insights

North America accounted for USD 4.18 billion in 2025 and is projected to reach USD 4.51 billion in 2026, driven by strong R&D activities and high disease prevalence. The U.S. remains the largest contributor in the region.

Europe held USD 2.28 billion in 2025 and is expected to reach USD 2.42 billion in 2026, supported by increasing cases of diabetes and cancer. Asia Pacific, valued at USD 1.0 billion in 2025, is projected to grow to USD 1.07 billion in 2026, driven by rising investments in pharmaceutical research.

Latin America and the Middle East & Africa are emerging markets, with increasing awareness and improving healthcare infrastructure supporting growth.

Competitive Landscape

The market is highly competitive, with key players such as Pfizer Inc., Novartis AG, Viatris Inc., and Abbott focusing on product innovation and strategic collaborations. Companies are investing in acquisitions and partnerships to strengthen their product portfolios and expand their global presence.

Recent developments, including new drug approvals and clinical trials, highlight the industry's commitment to advancing neuropathic pain treatment options.

Conclusion

The neuropathic pain market is expected to grow from USD 8.26 billion in 2025 to USD 16.78 billion by 2034, driven by the rising prevalence of chronic diseases, increasing geriatric population, and ongoing advancements in therapeutics. While challenges such as side effects and high costs persist, continuous innovation and expanding treatment options are expected to support sustained market growth.

Segmentation By Drug Class

  • Anticonvulsants
  • Tricyclic Antidepressants (TCA)
  • Opioids
  • Capsaicinoids
  • Others

By Application

  • Diabetic Neuropathy
  • Chemotherapy Induced Neuropathy
  • Sciatic Neuropathy
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and BY Country/Sub-region)
    • Japan
    • China
    • Australia
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
    • South Africa
    • GCC
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Neuropathic pain - by Key Countries/Sub-regions, 2025
  • 4.2. Pipeline Analysis - by Key Players
  • 4.3. New Product launches - by Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Anticonvulsants
    • 5.1.2. Tricyclic Antidepressant (TCA)
    • 5.1.3. Opioids
    • 5.1.4. Capsaicinoids
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Diabetic Neuropathy
    • 5.2.2. Chemotherapy Induced Neuropathy
    • 5.2.3. Sciatic Neuropathy
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy
    • 5.4.3. Online Pharmacy
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Anticonvulsants
    • 6.1.2. Tricyclic Antidepressant (TCA)
    • 6.1.3. Opioids
    • 6.1.4. Capsaicinoids
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Diabetic Neuropathy
    • 6.2.2. Chemotherapy Induced Neuropathy
    • 6.2.3. Sciatic Neuropathy
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy
    • 6.4.3. Online Pharmacy
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Anticonvulsants
    • 7.1.2. Tricyclic Antidepressant (TCA)
    • 7.1.3. Opioids
    • 7.1.4. Capsaicinoids
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Diabetic Neuropathy
    • 7.2.2. Chemotherapy Induced Neuropathy
    • 7.2.3. Sciatic Neuropathy
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Online Pharmacy
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Anticonvulsants
    • 8.1.2. Tricyclic Antidepressant (TCA)
    • 8.1.3. Opioids
    • 8.1.4. Capsaicinoids
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Diabetic Neuropathy
    • 8.2.2. Chemotherapy Induced Neuropathy
    • 8.2.3. Sciatic Neuropathy
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Pharmacy
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. Japan
    • 8.5.2. Australia
    • 8.5.3. China
    • 8.5.4. India
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Anticonvulsants
    • 9.1.2. Tricyclic Antidepressant (TCA)
    • 9.1.3. Opioids
    • 9.1.4. Capsaicinoids
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Diabetic Neuropathy
    • 9.2.2. Chemotherapy Induced Neuropathy
    • 9.2.3. Sciatic Neuropathy
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Online Pharmacy
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Anticonvulsants
    • 10.1.2. Tricyclic Antidepressant (TCA)
    • 10.1.3. Opioids
    • 10.1.4. Capsaicinoids
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Diabetic Neuropathy
    • 10.2.2. Chemotherapy Induced Neuropathy
    • 10.2.3. Sciatic Neuropathy
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. South Africa
    • 10.5.2. GCC
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Almatica
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Azurity Pharmaceuticals, Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Pfizer Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Viatris Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Supernus Pharmaceuticals, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Novartis AG
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Accord Healthcare
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Focus Health Group
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Amneal Pharmaceuticals LLC
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Abbott
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Teva Pharmaceutical Industries Ltd.
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Neuropathic Pain Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Neuropathic Pain Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 3: Global Neuropathic Pain Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Neuropathic Pain Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Neuropathic Pain Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Neuropathic Pain Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Neuropathic Pain Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 8: North America Neuropathic Pain Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Neuropathic Pain Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Neuropathic Pain Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Neuropathic Pain Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 12: Europe Neuropathic Pain Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 13: Europe Neuropathic Pain Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Neuropathic Pain Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Neuropathic Pain Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Neuropathic Pain Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 17: Asia Pacific Neuropathic Pain Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 18: Asia Pacific Neuropathic Pain Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 19: Asia Pacific Neuropathic Pain Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 20: Latin America Neuropathic Pain Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 21: Latin America Neuropathic Pain Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 22: Latin America Neuropathic Pain Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 23: Latin America Neuropathic Pain Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 24: Middle East & Africa Neuropathic Pain Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 25: Middle East & Africa Neuropathic Pain Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 26: Middle East & Africa Neuropathic Pain Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 27: Middle East & Africa Neuropathic Pain Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Neuropathic Pain Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Neuropathic Pain Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Neuropathic Pain Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Neuropathic Pain Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 5: Global Neuropathic Pain Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Neuropathic Pain Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Neuropathic Pain Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 8: North America Neuropathic Pain Market Value Share (%), by Drug Class, 2025
  • Figure 9: North America Neuropathic Pain Market Value (USD billion), by Application, 2025 & 2034
  • Figure 10: North America Neuropathic Pain Market Value Share (%), by Application, 2025
  • Figure 11: North America Neuropathic Pain Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 12: North America Neuropathic Pain Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Neuropathic Pain Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Neuropathic Pain Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Neuropathic Pain Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Neuropathic Pain Market Value Share (%), By Country, 2025
  • Figure 17: Europe Neuropathic Pain Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 18: Europe Neuropathic Pain Market Value Share (%), by Drug Class, 2025
  • Figure 19: Europe Neuropathic Pain Market Value (USD billion), by Application, 2025 & 2034
  • Figure 20: Europe Neuropathic Pain Market Value Share (%), by Application, 2025
  • Figure 21: Europe Neuropathic Pain Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Neuropathic Pain Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Neuropathic Pain Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Neuropathic Pain Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Neuropathic Pain Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Neuropathic Pain Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Neuropathic Pain Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 28: Asia Pacific Neuropathic Pain Market Value Share (%), by Drug Class, 2025
  • Figure 29: Asia Pacific Neuropathic Pain Market Value (USD billion), by Application, 2025 & 2034
  • Figure 30: Asia Pacific Neuropathic Pain Market Value Share (%), by Application, 2025
  • Figure 31: Asia Pacific Neuropathic Pain Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Neuropathic Pain Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Neuropathic Pain Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Neuropathic Pain Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Neuropathic Pain Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Neuropathic Pain Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Neuropathic Pain Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Latin America Neuropathic Pain Market Value Share (%), by Drug Class, 2025
  • Figure 39: Latin America Neuropathic Pain Market Value (USD billion), by Application, 2025 & 2034
  • Figure 40: Latin America Neuropathic Pain Market Value Share (%), by Application, 2025
  • Figure 41: Latin America Neuropathic Pain Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Neuropathic Pain Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Neuropathic Pain Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Neuropathic Pain Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Neuropathic Pain Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Neuropathic Pain Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Neuropathic Pain Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 48: Middle East & Africa Neuropathic Pain Market Value Share (%), by Drug Class, 2025
  • Figure 49: Middle East & Africa Neuropathic Pain Market Value (USD billion), by Application, 2025 & 2034
  • Figure 50: Middle East & Africa Neuropathic Pain Market Value Share (%), by Application, 2025
  • Figure 51: Middle East & Africa Neuropathic Pain Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Neuropathic Pain Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Neuropathic Pain Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Neuropathic Pain Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Neuropathic Pain Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Neuropathic Pain Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Neuropathic Pain Market Share (%), By Company, 2025